Merck + Co., Inc.

Other

Schering Aktiengesellschaft

George E Mark, Iii

Gregory Franklin Hollis

Steven W Ludmerer

Diana Benincasa

Bruce L Daugherty

Eduardo Agustin Padlan

Paul A Friedman

Le T Duong

Sunil K Gupta

Jwu-Sheng Tung

Simon W Law

Melvin Silberklang

Linda O Palladino

John W Jacobs

Stephen J Gardell

Richard A Dixon

A unique method is disclosed for identifying and replacing immunoglobulin surface amino acid residues which converts the antigenicity of a first mammalian species to that of a second mammalian species. The method will simultaneously change immunogenicity and strictly preserve ligind binding properties. The judicious replacement of exterior amino acid residues has no effect on the ligind binding properties but greatly alters immunogenicity.

Method for reducing the immunogenicity of antibody variable domains

A specific locus in the genome of a murine host cell is identified which causes high levels of recombinant gene expression following stable integration, via homologous recombination, of the recombinant gene into the specific chromosomal locus. The selection of a favorable genome locus for the insertion and expression of a recombinant gene is disclosed, as are DNA vectors and host cells.

Homologous recombination antibody expression system for murine cells

Vaccine formulations comprising recombinant early (E) and late (L) proteins of papillomavirus and oxidized mannan as well as methods of making and using the formulations are provided.

Formulations of recombinant papillomavirus vaccines

Purified plasminogen activator proteins obtained or derived from the vampire bat Desmodus rotundus saliva and salivary glands, methods for purifying the proteins, DNA sequences encoding these proteins, means for producing them using recombinant DNA technology, pharmaceutical compositions comprising these proteins and methods of treatment utilizing these proteins are provided.

Vampire bat salivary plasminogen activators

The present invention is a series of synthetic virus-like particles useful in the characterization of human papillomavirus infection and assays employing the synthetic virus-like particles.

Synthetic HPV11 virus-like particles

The present invention is a series of synthetic virus-like particles useful in the characterization of human papillomavirus infection and assays employing the synthetic virus-like particles. The synthetic virus-like particles are generated from constructs designated as HPV6:4; HPV6:5; HPV6:2; HPV6:4.DELTA.132; and HPV6:4,S131G.

A protein having a molecular weight of about 6,000 daltons which is biologically active in the inhibition of Factor Xa during the blood coagulation cascade, a method for producing the protein, methods for inhibiting blood coagulation using the protein, and suitable pharmaceutical compositions.

Growing community of inventors

Princeton Junction, NJ, United States of America

George E Mark, Iii